National Center for Complementary & Alternative Medicines; Notice of Meeting, 40317 [07-3587]

Download as PDF Federal Register / Vol. 72, No. 141 / Tuesday, July 24, 2007 / Notices purses inspected or x-rayed as they enter NIH buildings. For more information about the new security measures at NIH, please visit the Web site at http://www.nih.gov/about/ visitorsecurity.htm. Dated: July 12, 2007. Raynard S. Kington, Deputy Director, National Institutes of Health. [FR Doc. E7–14208 Filed 7–23–07; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Center for Complementary & Alternative Medicines; Notice of Meeting mstockstill on PROD1PC66 with NOTICES Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the National Advsiory Council for Complementary and Alternate Medicine (NACCAM) meeting. The meetings will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. A portion of the meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and/or contract proposals and the discussion could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications and/or contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Advisory Council for Complementary and Alternative Medicine. Date: September 5, 2007. Time: 8 a.m. to 12 p.m. Agenda: To review and evaluate grant applications and/or proposals. Open: 1 p.m. to 4:30 p.m. Agenda: Opening remarks by the Acting Director of National Center for Complementary and Alternative Medicine, presentation of a new research alternative, and other business of the Council. Place: National Institutes of Health, Neuroscience Building, 6001 Executive Boulevard, Conference Rooms C & D, Bethesda, MD 20882. Contact Person: Martin H. Goldrosen, Executive Secretary, National Center for Complementary and Alternative Medicine, VerDate Aug<31>2005 19:13 Jul 23, 2007 Jkt 211001 National Institutes of Health, 6707 Democracy Blvd., Suite 401, Bethesda, MD 20892, (301) 594–2014. The public comments session is scheduled from 4–4:30 p.m., but could change depending on the actual time spent on each agenda item. Each speaker will be permitted 5 minutes for their presentation. Interested individuals and representatives of organizations are requested to notify Dr. Martin H. Goldrosen, National Center for Complementary and Alternative Medicine, NIH, 6707 Democracy Boulevard, Suite 401, Bethesda, Maryland, 20892, 301–594–2014, Fax: 301–480–9970. Letters of intent to present comments, along with a brief description of the organization represented, should be received no later than 5 p.m. on September 3, 2007. Only one representative of an organization may present oral comments. Any person attending the meeting who does not request an opportunity to speak in advance of the meeting may be considered for oral presentation, if time permits, and at the discretion of the Chairperson. In addition, written comments may be submitted to Dr. Martin H. Goldrosen at the address listed above up to ten calendar days (September 15, 2007) following the meeting. Copies of the meeting agenda and the roster of members will be furnished upon request by contacting Dr. Martin H. Goldrosen, Executive Secretary, NACCAM, National Center for Complementary and Alternative Medicine, National Institutes of Health, 6707 Democracy Boulevard, Suite 401, Bethesda, Maryland 20892, 301–594– 2014, Fax 301–480–9970, or via e-mail at naccames@mail.nih.gov. In the interest of security, NIH has instituted stringent procedures for entrance into the building by nongovernment employees. Persons without a government I.D. will need to show a photo I.D. and sign in at the security desk upon entering the building. Dated: July 17, 2007. Jennifer Spaeth, Director, Office of Federal Advisory Committee Policy. [FR Doc. 07–3587 Filed 7–23–07; 8:45 am] 40317 commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constituet a clearly unwarranted invasion of personal constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Heart, Lung, and Blood Institute Special Emphasis Panel, NIAID HIV/AIDS Scientific and Operations Support. Date: August 7, 2007. Time: 8 a.m. to 12 p.m. Agenda: To review and evaluate contract proposals. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Telephone Conference Call). Contact Person: Robert B. Moore, PhD, Health Scientist Administrator, Review Branch/DERA, National Heart, Lung, and Blood Institute, 6701 Rockledge Drive, Room 7202, Bethesda, MD 20892, 301 435–0050, mooreb@nhlbi.nih.gov. This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle. (Catalogue of Federal Domestic Assistance Program Nos. 93.233, National Center for Sleep Disorders Research; 93.837, Heart and Vascular Diseases Research; 93.38, Lung Diseases Research; 93.839, Blood Diseases and Resources Research, National Institutes of Health, HHS) Dated: July 17, 2007. Jennifer Spaeth, Director, Office of Federal Advisory Committee Policy. [FR Doc. 07–3586 Filed 7–23–07; 8:45 am] BILLING CODE 4140–07–M DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health BILLING CODE 4140–01–M National Institute on Drug Abuse; Notice of Meeting DEPARTMENT OF HEALTH AND HUMAN SERVICES Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the National Advisory Council on Drug Abuse. The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., National Institutes of Health National Heart, Lung and Blood Institute; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6Z), Title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets or PO 00000 Frm 00048 Fmt 4703 Sfmt 4703 E:\FR\FM\24JYN1.SGM 24JYN1

Agencies

[Federal Register Volume 72, Number 141 (Tuesday, July 24, 2007)]
[Notices]
[Page 40317]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 07-3587]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Center for Complementary & Alternative Medicines; Notice 
of Meeting

     Pursuant to section 10(d) of the Federal Advisory Committee Act, 
as amended (5 U.S.C. Appendix 2), notice is hereby given of the 
National Advsiory Council for Complementary and Alternate Medicine 
(NACCAM) meeting.
    The meetings will be open to the public as indicated below, with 
attendance limited to space available. Individuals who plan to attend 
and need special assistance, such as sign language interpretation or 
other reasonable accommodations, should notify the Contact Person 
listed below in advance of the meeting.
    A portion of the meeting will be closed to the public in accordance 
with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), 
Title 5 U.S.C., as amended. The grant applications and/or contract 
proposals and the discussion could disclose confidential trade secrets 
or commercial property such as patentable material, and personal 
information concerning individuals associated with the grant 
applications and/or contract proposals, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

     `Name of Committee: National Advisory Council for Complementary 
and Alternative Medicine.
    Date: September 5, 2007.
    Time: 8 a.m. to 12 p.m.
    Agenda: To review and evaluate grant applications and/or 
proposals.
    Open: 1 p.m. to 4:30 p.m.
    Agenda: Opening remarks by the Acting Director of National 
Center for Complementary and Alternative Medicine, presentation of a 
new research alternative, and other business of the Council.
    Place: National Institutes of Health, Neuroscience Building, 
6001 Executive Boulevard, Conference Rooms C & D, Bethesda, MD 
20882.
    Contact Person: Martin H. Goldrosen, Executive Secretary, 
National Center for Complementary and Alternative Medicine, National 
Institutes of Health, 6707 Democracy Blvd., Suite 401, Bethesda, MD 
20892, (301) 594-2014.
    The public comments session is scheduled from 4-4:30 p.m., but 
could change depending on the actual time spent on each agenda item. 
Each speaker will be permitted 5 minutes for their presentation. 
Interested individuals and representatives of organizations are 
requested to notify Dr. Martin H. Goldrosen, National Center for 
Complementary and Alternative Medicine, NIH, 6707 Democracy 
Boulevard, Suite 401, Bethesda, Maryland, 20892, 301-594-2014, Fax: 
301-480-9970. Letters of intent to present comments, along with a 
brief description of the organization represented, should be 
received no later than 5 p.m. on September 3, 2007. Only one 
representative of an organization may present oral comments. Any 
person attending the meeting who does not request an opportunity to 
speak in advance of the meeting may be considered for oral 
presentation, if time permits, and at the discretion of the 
Chairperson. In addition, written comments may be submitted to Dr. 
Martin H. Goldrosen at the address listed above up to ten calendar 
days (September 15, 2007) following the meeting.
    Copies of the meeting agenda and the roster of members will be 
furnished upon request by contacting Dr. Martin H. Goldrosen, 
Executive Secretary, NACCAM, National Center for Complementary and 
Alternative Medicine, National Institutes of Health, 6707 Democracy 
Boulevard, Suite 401, Bethesda, Maryland 20892, 301-594-2014, Fax 
301-480-9970, or via e-mail at naccames@mail.nih.gov.
    In the interest of security, NIH has instituted stringent 
procedures for entrance into the building by nongovernment 
employees. Persons without a government I.D. will need to show a 
photo I.D. and sign in at the security desk upon entering the 
building.

    Dated: July 17, 2007.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 07-3587 Filed 7-23-07; 8:45 am]
BILLING CODE 4140-01-M